← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 DELISTED 2seventy bio TSVT	128	+128	–	$816M
27	27 Lineage Cell Therapeutics LCTX $250M	124	+9	+8%	$182M
28	28 Ocugen OCGN $276M	122	+6	+5%	$291M
29	TCRR 29 DELISTED TCR2 Therapeutics Inc. Common Stock TCRR	122	+5	+4%	$136M
30	RUBY 30 DELISTED Rubius Therapeutics, Inc RUBY	108	+3	+3%	$864M
31	31 Cartesian Therapeutics RNAC $199M	106	+3	+3%	$186M
32	32 Sana Biotechnology SANA $742M	105	+17	+19%	$1.73B
33	ATNX 33 DELISTED Athenex, Inc. Common Stock ATNX	103	-13	-11%	$65.3M
34	34 MeiraGTx Holdings MGTX $950M	99	+18	+22%	$673M
35	35 Passage Bio PASG $11.6M	99	-2	-2%	$278M
36	36 DELISTED Adverum Biotechnologies ADVM	98	-12	-11%	$119M
37	37 DELISTED Carisma Therapeutics CARM	93	-10	-10%	$42.2M
38	38 Caribou Biosciences CRBU $49.8M	93	+5	+6%	$465M
39	39 Nkarta NKTX $138M	92	+5	+6%	$367M
40	40 ProKidney PROK $305M	90	+6	+7%	$227M
41	41 DELISTED Generation Bio GBIO	88	+7	+9%	$390M
42	ADAP 42 DELISTED Adaptimmune Therapeutics ADAP	85	-7	-8%	$426M
43	43 Mustang Bio MBIO $2.93M	83	+4	+5%	$46.4M
44	44 Fortress Biotech FBIO $63.7M	82	+3	+4%	$81.1M
45	45 Lakefront Biotherapeutics American Depositary Shares LKFT $1.96B	82	+1	+1%	$595M
46	46 Solid Biosciences SLDB $615M	82	-9	-10%	$132M
47	47 Adicet Bio ACET $48.1M	81	+23	+40%	$531M
48	48 Neurogene NGNE $479M	80	-5	-6%	$119M
49	49 4D Molecular Therapeutics FDMT $711M	77	+14	+22%	$542M
50	50 Lyell Immunopharma LYEL $201M	77	+15	+24%	$662M